Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Chief Innovation Officer | August 22, 2025 | August 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date August 22, 2025 · Filed August 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,449 |
Reported balance
After 2025-08-22 transaction · row 1
1 source rowRow 1 · 2025-08-22 · Grant · Acquired 30,000 · Balance 110,449 F1: Represents grant of performance stock which vested on August 22, 2025 |
| Common StockSEC Table I · non-derivative | IndirectBy American Nutra Tech, LLC | 1,644,800 |
Reported balance
Holding disclosure · report date 2025-08-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,644,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of performance stock which vested on August 22, 2025
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2025 Filed Aug 26, 2025 22:18 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000915 · form4.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,449 F1 · price: Represents grant of performance stock which vested on August 22, 2025 Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:13 UTC | LifeMD, Inc. LFMD · Entity 6521 | SaleCommon Stock | 85,000 | $12.38 | $1,052,657.00 |
DisclosureSEC source: 0000912282-25-000683 · form4.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,449 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 and $12.4900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:50 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000363 · form4.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,449 F1 · price: Represents grant of performance stock which vested on March 31, 2025. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:13 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000282 · form4.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,449 F1 · price: Represents grant of performance stock which vested on March 7, 2025. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:50 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Shares | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000265 · form4.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,449 F1 · shares: Represents grant of restricted shares which vests on January 1 2026. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 18:10 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 3,000 | $4.93 | $14,790.00 |
DisclosureSEC source: 0001362118-24-000022 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,449 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $4.9299 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 17:25 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-24-000010 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,449 F1 · price: Performance shares vested on March 21, 2024. Read SEC document |
| May 23, 2023 Filed May 23, 2023 19:28 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 10,000 | $2.17 | $21,700.00 |
DisclosureSEC source: 0001362118-23-000032 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,841 Read SEC document |
| May 23, 2023 Filed May 31, 2023 11:15 UTC Amendment | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 4,608 | $2.17 | $9,999.36 |
DisclosureSEC source: 0001362118-23-000035 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,449 F1 · shares: This Form 4 corrects the number of shares purchased. Read SEC document |
| December 28, 2022 Filed Feb 6, 2023 21:40 UTC | LifeMD, Inc. LFMD · Entity 6521 | GiftCommon Stock, par value $0.01 | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-23-000006 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By American Nutra Tech, LLC Disclosed balance after: 1,644,800 Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 15:03 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 542 | $4.81 | $2,607.02 |
DisclosureSEC source: 0001362118-21-000043 · primary_doc.xml · nonDerivative · entry 3 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,841 Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 15:03 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 1,206 | $4.80 | $5,788.80 |
DisclosureSEC source: 0001362118-21-000043 · primary_doc.xml · nonDerivative · entry 2 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,299 Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 15:03 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 100 | $4.79 | $479.00 |
DisclosureSEC source: 0001362118-21-000043 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,093 Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 20:17 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 100 | $4.54 | $454.00 |
DisclosureSEC source: 0001362118-21-000042 · primary_doc.xml · nonDerivative · entry 2 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,993 Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 20:17 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 2,097 | $4.55 | $9,541.35 |
DisclosureSEC source: 0001362118-21-000042 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,893 Read SEC document |
| May 19, 2021 Filed May 21, 2021 15:54 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 3,796 | $10.40 | $39,478.40 |
DisclosureSEC source: 0001362118-21-000014 · primary_doc.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,796 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 22:28 UTC | LifeMD, Inc. CVLB · Entity 6521 | GrantCommon Stock, par value $0.01 | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-023420 · ownership.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · American Nutra Tech, LLC. Disclosed balance after: 1,749,000 F1 · kind: The shares were issued to Mr. Galluppi for having achieved certain performance milestones pursuant to a Membership Interest Purchase Agreement, dated April 25, 2019, by and between the Issuer, Conversion Labs PR LLC, Taggart International Trust, and American Nutra Tech LLC, an entity controlled by Mr. Galluppi. F1 · price: The shares were issued to Mr. Galluppi for having achieved certain performance milestones pursuant to a Membership Interest Purchase Agreement, dated April 25, 2019, by and between the Issuer, Conversion Labs PR LLC, Taggart International Trust, and American Nutra Tech LLC, an entity controlled by Mr. Galluppi. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 21:26 UTC | LifeMD, Inc. CVLB · Entity 6521 | SaleCommon Stock, par value $0.01 | 401,000 | $1.00 | $401,000.00 |
DisclosureSEC source: 0001493152-20-018295 · ownership.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · American Nutra Tech, LLC. Disclosed balance after: 749,000 F1 · ownership.nature: Mr. Galluppi has sole voting and dispositive power over American Nutra Tech, LLC Read SEC document |
| April 25, 2019 Filed Jul 22, 2019 12:55 UTC | LifeMD, Inc. CVLB · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 4,687 | $0.16 | $749.92 |
DisclosureSEC source: 0001213900-19-013247 · ownership.xml · nonDerivative · entry 1 Galluppi Stefan · CIK 0001722649 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,687 F1 · kind: These shares were purchased on the open market. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.